Hologic, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
6.1
Neutral
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
HOLX
Clean balance sheet with low leverage (0.5× debt-to-equity).
⚠ cautious analyst consensus — few Buy ratings.
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $76.67 (+0.9%)
9 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
HOLX
JNJ
31.5×
Trailing P/E
26.3×
15.6×
Forward P/E
17.9×
13.2%
Profit Margin
21.8%
60.4%
Gross Margin
68.0%
10.9%
ROE
26.4%
2.5%
Revenue Growth
9.9%
-9.2%
Earnings Growth
-52.9%
0.70
Beta
0.33
—
Price / Book
—
$17.0B
Market Cap
$546.9B
$52 – $76
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →